Alzheon, Inc. | Preserving Future Memories

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimers clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimers patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance...

Alzheimer's disease,drug development,neurodegeneration,and biotechnology

Alzheon, inc. | preserving future memories operates in the Biotechnology research industry.

Alzheon, inc. | preserving future memories's revenue is 11m - 100m

Alzheon, inc. | preserving future memories has 11 - 50 employees.